Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22836884 | 0.86 | CFTR (0.45) | GAACFTRMAPTSMN1; SMN2HPGD | |
| SCHEMBL3872035 | 0.85 | CFTR (0.50) | GAACFTRMAPTHPGDLMNA | |
| SCHEMBL1110997 | 0.85 | GAA (0.57) | GAAMAPTSMN1; SMN2HPGDLMNA | |
| SCHEMBL11922634 | 0.84 | CFTR (0.49) | GAACFTRMAPTHPGDLMNA | |
| SCHEMBL2849661 | 0.84 | CFTR (0.45) | GAACFTRMAPTSMN1; SMN2HPGD | |
| SCHEMBL6739150 | 0.82 | LMNA (0.45) | GAAMAPTSMN1; SMN2HPGDLMNA | |
| Water SCHEMBL27598988 | 0.81 | GAA (0.45) | GAAMAPTSMN1; SMN2HPGDLMNA | |
| SCHEMBL15543856 | 0.81 | CFTR (0.46) | GAACFTRMAPTSMN1; SMN2HPGD | |
| SCHEMBL17239556 | 0.81 | CFTR (0.43) | GAACFTRMAPTSMN1; SMN2HPGD | |
| SCHEMBL7948445 | 0.81 | NR4A2 (0.46) | GAACFTRMAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6617344-B2 | Suitable as antiarrhythmic pharmaceuticals having a cardioprotective component for infarct prophylaxis and infarct treatment, and also for the treatment of angina pectoris. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-09 | — | — | US | disclosed |
| US-20030139607-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTICS, AND MEDICAMENTS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-07-24 | — | — | US | disclosed |
| CN-1373757-A | Heterocyclically substd, benzoylguanidine, method for production thereof, use thereof as medicament or means of diagnosis and medicaments contg. same | AVENTIS PHARMA GMBH (DE) | 2002-10-09 | — | — | CN | disclosed |
| US-20020099222-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | WEICHERT ANDREAS (DE) | 2002-07-25 | — | — | US | disclosed |
| US-20010049446-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | WEICHERT ANDREAS (DE) | 2001-12-06 | — | — | US | disclosed |
| US-6057322-A | USEFUL IN TREATMENT OF CARDIOVASCULAR DISEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099222-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | TNNI3, HBG1, TNNT2 | GAA 763/4885CFTR 3411/4885MAPT 4865/4885 |
| US-20010049446-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | TNNI3, HBG1, TNNT2 | GAA 763/4885CFTR 3411/4885MAPT 4865/4885 |
| US-20030139607-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTICS, AND MEDICAMENTS COMPRISING THEM | TNNI3, HBG1, TNNT2 | GAA 763/4885CFTR 3411/4885MAPT 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.